相关实验视频

Updated: Jan 18, 2026

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

在LPS引起的急性肺损伤中,MST1通过准NF-κB/NLRP3通路来调节炎症反应

Zi-Xi Peng¹, Lin-Li Song¹, Xiao-Li Wang²

¹Medical College of Jishou University, Jishou, 416000, Hunan, P. R. China.

Histochemistry and cell biology

|May 28, 2025

概括

哺乳动物STE20样蛋白激酶1 (MST1) 通过激活NF-κB和NLRP3通路,加剧急性肺损伤 (ALI) 中的炎症. 抑制MST1可能为ALI患者提供新的治疗策略.

科学领域:

肺部医学肺部医学
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

急性肺损伤 (ALI) 是一种严重的呼吸系统疾病,炎症在其中起着关键作用.
哺乳动物STE20样蛋白激酶1 (MST1) 与脂代谢和炎症反应有关,但其在ALI中的作用尚未完全理解.

研究的目的:

研究MST1在脂聚糖 (LPS) 诱导的ALI中的作用和机制.
探索MST1对ALI炎症和氧化应激途径的影响.

主要方法:

在RAW 264.7细胞和小鼠中建立了LPS诱导的ALI模型.
评估肺损伤,炎症标志物 (细胞因子,MPO) 和氧化应激 (SOD,MDA).
分析了使用RT-qPCR和西部涂抹的NF-κB和NLRP3信号通路激活,通过lentiviral转染进行MST1调制.

主要成果:

在体内,MST1抑制减轻了肺损伤,炎症和氧化应激.
在体外,MST1过度表达促进了细胞增殖和炎症.
在体内和体外的结果显示MST1调节NF-κB和NLRP3信号通路.

结论:

通过激活NF-κB/NLRP3信号通路,MST1激活有助于LPS诱导的ALI炎症.
向MST1为治疗ALI提供了一个潜在的新疗法策略.

关键词:

急性肺损伤是什么?急性肺损伤是什么?炎症炎症是一种炎症.在MST1中,它是MST1.在NF-κB/NLRP3信号通路中.

更多相关视频

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury

Visualizing Lung Cellular Adaptations during Combined Ozone and LPS Induced Murine Acute Lung Injury

Published on: March 21, 2021

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

相关概念视频

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms: